Patient-reported symptoms and interest in symptom monitoring in HCC treated with locoregional therapies: A qualitative study.

Andrew M MoonSarah CookRachel M SwierHanna K SanoffMichael D Kappelman Lynne I Wagner Alfred Sidney Barritt Amit G Singal Neil D Shah David M Mauro Ted K YanagiharaDavid A GerberMichael W FriedCristal BrownMyra WaheedRandall TealDonna M Evon

Published in: Hepatology communications (2023)

Posttreatment symptoms after HCC locoregional therapies are common and often severe. These data can inform and prioritize PRO domain selection. Patients are interested in ePRO monitoring to monitor and proactively address posttreatment symptoms. Given the clinical benefits in patients with metastatic cancers, ePRO monitoring warrants investigation in patients with HCC.

Keyphrases

patient reported
newly diagnosed
end stage renal disease
ejection fraction
sleep quality
prognostic factors
machine learning
young adults
physical activity